SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999; 281: 16051510.
  • 2
    Confortini M, Carozzi F, Dalla Palma P, et al., and the GISCi Working Group for Cervical Cytology. Interlaboratory reproducibility of atypical cells of undetermined significance (ASCUS) report: a national survey. Cytopathology. In press.
  • 3
    Cecchini S, Iossa A, Bonardi R, Ciatto S, Cariaggi P. Comparing two modalities of management of women with cytologic evidence of squamous or glandular atypia: early repeat cytology or colposcopy. Tumori. 1997; 83: 732734.
  • 4
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System terminology for reporting results of cervical cytology. JAMA. 2002; 287: 21142119.
  • 5
    Solomon D, Schiffman M, Tarone B, for The ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from randomised trial. J Natl Cancer Inst. 2001; 93: 203209.
  • 6
    Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287: 21202129.
  • 7
    Cecchini S, Piazzesi G, Carli S. Sensitivity of the screening program for cervical in the Florence district. Gynecol Oncol. 1989; 33: 182184.
  • 8
    Palli D, Carli S, Cecchini S, Venturini A, Piazzesi G, Buiatti E. A centralized cytology screening programme for cervical cancer in Florence. J Epidemiol Commun Health. 1990; 4: 4144.
  • 9
    Ciatto S, Cecchini S, Bonardi R, Venturini A, Ciacci R. Attendance to a screening program for cervical cancer in the city of Florence. Tumori. 1991; 30: 252256.
  • 10
    Carozzi F, Cariaggi P, Bonardi L, et al. Clinical impact (cost-effectiveness) of qualifying atypical squamous cell of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic process. Diagn Cytopathol. 2003; 29: 47.
  • 11
    Carozzi F, Confortini M, Cecchini S, Ciatto S. HPV testing for cervical neoplasia. Acta Cytol. 2001; 45: 659661.
  • 12
    Carozzi F, Ronco G, Confortini M, et al. Prediction of high grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br J Cancer. 2000; 83: 14621467.
  • 13
    Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato J, Fujinaga K. Simultaneous detection and typing of genital papilloma virus DNA using the polymerase chain reaction. J Gen Virol. 1991; 72: 10391044.
  • 14
    Bauer HM, Greer CE, Manos MM. Determination of genital human papillomavirus infection by consensus PCR amplification. In: HerringtonCS, O'D McGeeJ, editors. Diagnostic molecular pathology: a practical approach. Oxford: Oxford University Press; 1992: 131152.
  • 15
    Zappa M, Cecchini S, Ciatto S, et al. Measurement of the cost of screening for cervical cancer in the district of Florence, Italy. Tumori. 1998; 84: 631635.
  • 16
    The IARC Working Group on Cervical Cancer Screening and the UICC Project Group on the Evaluation of Screening Programmes for Cancer. Screening for cancer of the uterine cervix. IARC Sci Publ. 1986; 76: 1315.
  • 17
    Carozzi F, Confortini M, Cecchini S, Ciatto S. HPV testing for cervical neoplasia. Acta Cytol. 2001; 45: 659661.
  • 18
    Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619631.